Core Laboratories
CLB
197 hedge funds and large institutions have $830M invested in Core Laboratories in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 74 increasing their positions, 55 reducing their positions, and 23 closing their positions.
615% more call options, than puts
Call options by funds: $7.31M | Put options by funds: $1.02M
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
35% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 55
6% more funds holding
Funds holding: 186 → 197 (+11)
4% less capital invested
Capital invested by funds: $868M → $830M (-$38.6M)
1.51% less ownership
Funds ownership: 105.26% → 103.75% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$28.9M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$5.61M |
| 3 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$3.79M |
| 4 |
RA
Royce & Associates
New York
|
+$3.16M |
| 5 |
GJL
Gendell Jeffrey L
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$24.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$12M |
| 3 |
EARNEST Partners
Atlanta,
Georgia
|
-$10M |
| 4 |
Morgan Stanley
New York
|
-$6.47M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$4.81M |
CLB Hedge Fund Activity: Q1 2024 in Review
197 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Core Laboratories (CLB) for Q1 2024, worth a combined $830M — down 4.4% from $868M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CLB positions and 23 closed out — a net gain of 11 holders — while 74 added to existing stakes and 55 trimmed.
The largest buyer was Ariel Investments, adding an estimated $28.9M. The largest seller was Boston Trust Walden, cutting an estimated $24.4M.
- 197 institutional investors held Core Laboratories (CLB) as of Q1 2024, up from 186 in Q4 2023.
- Funds reported $830M of Core Laboratories stock for Q1 2024, down 4.4% quarter-over-quarter.
- 34 funds opened new Core Laboratories positions in Q1 2024 and 23 closed out, a net change of +11 holders.
- The largest Core Laboratories buyer in Q1 2024 was Ariel Investments, an estimated $28.9M added.
- The largest Core Laboratories seller in Q1 2024 was Boston Trust Walden, an estimated $24.4M sold.
Based on aggregated 13F filings for Q1 2024.